News Release Details
Opiant Pharmaceuticals, Inc. Provides an Update on NARCAN® Nasal Spray
NARCAN® Nasal Spray is marketed in the U.S. and
Recent highlights of the NARCAN® Nasal Spray include:
$25 millionof net sales for the first half of calendar 2017, triggering SWK Funding LLC’s obligation to pay Opiant an additional $3.75 million
- Mandatory co-prescribing of naloxone to patients receiving opioid prescriptions, who are considered at high risk of opioid overdose, in
- Recommended co-prescribing of naloxone with opioid painkillers by both the
Centers for Disease Control (CDC) and The Veterans Administration(VA)
- In over 40 states, NARCAN® Nasal Spray can now be purchased from pharmacies without a prescription
- Adapt has maintained the price of NARCAN® Nasal Spray, including a discounted public interest price of
$75per two-dose pack ( $37.50per dose).
“At a news conference in
Beyond NARCAN® Nasal Spray, Opiant remains committed to further innovation and product development in the addiction market. Opiant’s pipeline of nasal opioid antagonists address both Alcohol Use Disorder and Eating Disorders. These represent potentially larger market opportunities, but still allow a 505(b)(2) regulatory pathway for
Opiant is developing other products for Opioid Use Disorder, including advancing the pre-clinical development of its heroin vaccine candidate, which was licensed in
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.